[go: up one dir, main page]

WO1997037029B1 - ANTICORPS MONOCLONAUX SPECIFIQUES DU RECEPTEUR DU FACTEUR DE CROISSANCE DERIVE DES PLAQUETTE β ET PROCEDES D'UTILISATION DE CES ANTICORPS - Google Patents

ANTICORPS MONOCLONAUX SPECIFIQUES DU RECEPTEUR DU FACTEUR DE CROISSANCE DERIVE DES PLAQUETTE β ET PROCEDES D'UTILISATION DE CES ANTICORPS

Info

Publication number
WO1997037029B1
WO1997037029B1 PCT/US1997/004198 US9704198W WO9737029B1 WO 1997037029 B1 WO1997037029 B1 WO 1997037029B1 US 9704198 W US9704198 W US 9704198W WO 9737029 B1 WO9737029 B1 WO 9737029B1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
antibody according
pdgf
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/004198
Other languages
English (en)
Other versions
WO1997037029A1 (fr
Filing date
Publication date
Priority claimed from US08/621,751 external-priority patent/US5882644A/en
Application filed filed Critical
Priority to AU23298/97A priority Critical patent/AU2329897A/en
Publication of WO1997037029A1 publication Critical patent/WO1997037029A1/fr
Publication of WO1997037029B1 publication Critical patent/WO1997037029B1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Abstract

Cette invention se rapporte à des anticorps monoclonaux, à des anticorps monoclonaux humanisés et à des dérivés fonctionnels de ces anticorps, spécifiques du récepteur du facteur de croissance issu des plaquettes β. Des procédés d'utilisation de cet anticorps, en particulier pour soigner la resténose, sont également présentés.
PCT/US1997/004198 1996-03-22 1997-03-19 ANTICORPS MONOCLONAUX SPECIFIQUES DU RECEPTEUR DU FACTEUR DE CROISSANCE DERIVE DES PLAQUETTE β ET PROCEDES D'UTILISATION DE CES ANTICORPS Ceased WO1997037029A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU23298/97A AU2329897A (en) 1996-03-22 1997-03-19 Monoclonal antibodies specific for the platelet derived growth factor beta receptor and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/621,751 US5882644A (en) 1996-03-22 1996-03-22 Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US08/621,751 1996-03-22

Publications (2)

Publication Number Publication Date
WO1997037029A1 WO1997037029A1 (fr) 1997-10-09
WO1997037029B1 true WO1997037029B1 (fr) 1997-12-18

Family

ID=24491483

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/004198 Ceased WO1997037029A1 (fr) 1996-03-22 1997-03-19 ANTICORPS MONOCLONAUX SPECIFIQUES DU RECEPTEUR DU FACTEUR DE CROISSANCE DERIVE DES PLAQUETTE β ET PROCEDES D'UTILISATION DE CES ANTICORPS

Country Status (3)

Country Link
US (1) US5882644A (fr)
AU (1) AU2329897A (fr)
WO (1) WO1997037029A1 (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020009443A1 (en) * 1991-12-02 2002-01-24 Vanitha Ramakrishman Inhibitory immunoglobulin polypeptides to human pdgf beta receptor
US20020044933A1 (en) * 1993-02-25 2002-04-18 Hart Charles E. Inhibition of intimal hyperplasia using antibodies to PDGF receptors
US6114110A (en) * 1996-01-16 2000-09-05 University Of Michigan Isolation and propagation of a human herpesvirus derived from AIDS-associated Kaposi's sarcoma cells
WO1998035697A1 (fr) * 1997-02-14 1998-08-20 Roche Diagnostics Gmbh Procede ameliore permettant de reduire la formation de cellules neointimes apres une angioplastie
US6541225B1 (en) * 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
ITMI20002832A1 (it) * 2000-12-27 2002-06-27 Acetum S R L Salsa balsamica per uso alimentare a base di aceto balsamico di modena
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US7172758B2 (en) * 2002-01-29 2007-02-06 Colb A Mark Endothelialization of vascular surfaces
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
JP4951339B2 (ja) 2003-08-27 2012-06-13 オプソテツク・コーポレイシヨン 眼血管新生疾患の治療のための併用療法
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US20070207154A1 (en) * 2004-04-16 2007-09-06 Martin Friedlander Method of modulating vascularization
US20080213274A1 (en) * 2005-10-28 2008-09-04 Sabbadini Roger A Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
US7862812B2 (en) * 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
CL2007002225A1 (es) * 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
AU2007313822A1 (en) * 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
PT2087002E (pt) 2006-10-27 2014-11-26 Lpath Inc Composições e métodos para a ligação de esfingosina-1- fosfato
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (fr) * 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Méthode de traitement d'amyloïdoses
WO2008130704A2 (fr) 2007-04-17 2008-10-30 Imclone Llc Inhibiteurs spécifiques de pdgfrβ
CA2682605A1 (fr) * 2007-04-18 2008-10-30 Zymogenetics, Inc. Fc a chaine simple, procedes de fabrication et procedes de traitement
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
CA2724432A1 (fr) * 2007-05-30 2008-12-11 Lpath, Inc. Compositions et procedes pour lier de l'acide lysophosphatidique
AU2008262384B9 (en) 2007-06-05 2014-11-27 Yale University Inhibitors of receptor tyrosine kinases and methods of use thereof
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
SI2274008T1 (sl) * 2008-03-27 2014-08-29 Zymogenetics, Inc. Sestavki in metode za zaviranje PDGFRBETA in VEGF-A
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
US8401799B2 (en) * 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
KR20110097923A (ko) * 2008-12-05 2011-08-31 엘파스, 인크. 항-지질 항체 결정 구조를 이용한 항체 설계
EP2400985A2 (fr) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Thérapie anti-cancer combinée
WO2010098863A1 (fr) * 2009-02-26 2010-09-02 Lpath, Inc. Conception d'anticorps humanisé anti-facteur d'activation plaquettaire à l'aide de modèles d'anticorps anti-lipide
WO2010099138A2 (fr) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation
JP2012519281A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
EP2419446A4 (fr) * 2009-04-17 2013-01-23 Lpath Inc Compositions d'anticorps humanisés et procédés de liaison d'acide lysophosphatidique
TW201116297A (en) 2009-10-02 2011-05-16 Sanofi Aventis Antibodies that specifically bind to the EphA2 receptor
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
US20110212088A1 (en) * 2010-02-26 2011-09-01 Sabbadini Roger A Anti-paf antibodies
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
AU2011274363A1 (en) 2010-07-02 2013-01-24 Medimmune, Llc Antibody formulations
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
WO2012103165A2 (fr) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anticorps anti-kit et leurs utilisations
EP2702173A1 (fr) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer
TWI613215B (zh) 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
DK3381943T3 (da) 2012-07-25 2022-05-16 Celldex Therapeutics Inc Anti-kit-antistoffer og anvendelser deraf
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
DK3041513T3 (da) 2013-09-08 2020-10-26 Kodiak Sciences Inc Zwitterioniske faktor viii-polymerkonjugater
JP6768639B2 (ja) 2014-05-23 2020-10-21 セルデックス セラピューティクス，インコーポレーテッド 好酸球又はマスト細胞関連障害の治療
WO2015200905A2 (fr) * 2014-06-28 2015-12-30 Oligasis, Llc Doubles antagonistes de pdgf/vegf
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR102210104B1 (ko) 2014-10-17 2021-02-01 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
US20180044672A1 (en) 2015-03-20 2018-02-15 Johann Wolfgang Goethe-Universität Frankfurt am Main Pericyte Long Non-Coding RNAs
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
US20180362660A1 (en) * 2016-05-09 2018-12-20 Schickwann Tsai Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes
WO2019025299A1 (fr) 2017-07-31 2019-02-07 F. Hoffmann-La Roche Ag Procédé d'humanisation à base de structure tridimensionnelle
EP3758737A4 (fr) 2018-03-02 2022-10-12 Kodiak Sciences Inc. Anticorps anti-il-6 et constructions de fusion et conjugués associés
CN112334485B (zh) 2018-04-06 2024-09-27 百进生物科技公司 抗-四次穿膜蛋白33药剂及其组合物以及制备和使用方法
EP3856343A1 (fr) 2018-09-25 2021-08-04 Biolegend, Inc. Agents anti-tlr9 et compositions et procédés pour les préparer et les utiliser
CA3157509A1 (fr) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Procedes de traitement d'un trouble oculaire
WO2021146383A1 (fr) 2020-01-17 2021-07-22 BioLegend, Inc. Agents anti-tlr7 et compositions et procédés de fabrication et d'utilisation de ceux-ci
KR20220140551A (ko) * 2020-02-07 2022-10-18 바이오리온 테크놀러지스 비.브이. 혈소판 유래 성장 인자 수용체(pdgfr) 항체, 이의 컨쥬게이트, 조성물 및 용도
WO2022093641A1 (fr) 2020-10-30 2022-05-05 BioLegend, Inc. Agents anti-nkg2a et compositions et méthodes de production et d'utilisation de ceux-ci
WO2022093640A1 (fr) 2020-10-30 2022-05-05 BioLegend, Inc. Agents anti-nkg2c et compositions et méthodes de production et d'utilisation de ceux-ci
MX2024000057A (es) * 2021-07-02 2024-04-02 Laekna Therapeutics Shanghai Co Ltd Agotamiento de células estrelladas hepáticas (hscs) activadas y usos de estas.
CN119301155A (zh) 2022-07-19 2025-01-10 百进生物科技公司 抗cd157抗体、其抗原结合片段和组合物及其制备和使用方法
WO2024040114A2 (fr) 2022-08-18 2024-02-22 BioLegend, Inc. Anticorps anti-axl, leurs fragments de liaison à l'antigène et leurs procédés de fabrication et méthoes d'utilisation
WO2024243217A1 (fr) 2023-05-25 2024-11-28 BioLegend, Inc. Anticorps liant ceacam6 et fragments de liaison à l'antigène de ceux-ci
WO2025072313A1 (fr) 2023-09-27 2025-04-03 BioLegend, Inc. Anticorps anti-gpc4

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) * 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) * 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) * 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) * 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) * 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) * 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4754065A (en) * 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5468468A (en) * 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
IE920318A1 (en) * 1991-01-31 1992-07-29 Univ California Human platelet-derived growth factor receptors
PL171920B1 (pl) * 1991-12-02 1997-06-30 Cor Therapeutics Inc Sposób wytwarzania nowego, hamujacego PDGF-R polipeptydy immunoglobulinowego PL
DK0686044T3 (da) * 1993-02-25 2000-10-09 Zymogenetics Inc Hæmning af intimal hyperplasi under anvendelse af antistoffer mod PDGF-receptorer
US5620687A (en) * 1993-02-25 1997-04-15 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors

Similar Documents

Publication Publication Date Title
WO1997037029B1 (fr) ANTICORPS MONOCLONAUX SPECIFIQUES DU RECEPTEUR DU FACTEUR DE CROISSANCE DERIVE DES PLAQUETTE β ET PROCEDES D'UTILISATION DE CES ANTICORPS
Banerjee et al. Increased microtubule assembly in bovine brain tubulin lacking the type III isotype of beta-tubulin.
Soncin et al. Interaction of human angiogenin with copper modulates angiogenin binding to endothelial cells
Bayer et al. [4] Biotin-binding proteins: Overview and prospects
WO1998050431A3 (fr) Procede de preparation d'anticorps multispecifiques presentant des composants heteromultimeres
CA2128784C (fr) Complexes latents de haut poids moleculaire de tgf-beta2 et de tgf-beta3
EP0930366A3 (fr) Domaines de liaison de la protéine serrate
TWI318983B (en) An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
GR3036906T3 (en) Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof.
NZ507557A (en) Protein purification by ion exchange chromatography
UA40621C2 (uk) Моноклональне антитіло, гібридомна клітинна лінія, поліпептид (варіанти), фрагмент днк (варіанти), фармацевтична композиція, спосіб одержання моноклонального антитіла
IL181578A0 (en) Antibodies which are specifically immunoreactive with hedgehog interacting proteins and a hybridoma producing such antibodies
EP2172486A3 (fr) Anticorps monoclonal contre un prion et son utilisation pour la détection de prions
CA2430135A1 (fr) Anticorps recombinants anti-cd30 et utilisations de ceux-ci
CA2471762A1 (fr) Inhibiteurs peptidiques, a permeabilite cellulaire, du processus de transduction du signal jnk
AU6943800A (en) Antibodies specific for fullerenes
WO2000023565A3 (fr) Nouvelle liaison neuropiline/facteur de croissance et applications de celle-ci
EP1141271B1 (fr) Selection d'anticorps monoclonaux
MX9702422A (es) Anticuerpos recombinantes contra fas y adn para los mismos.
WO1995000552B1 (fr) Ce recepteur ep3 de prostaglandines et adn codant
CA2133873A1 (fr) Inhibiteurs du facteur de necrose tumorale (tnf)
WO1999046386B1 (fr) REACTIONS DE ALK-1 AU TGF-β ET DES SIGNAUX TRAVERSANT SMAD-1 ET SMAD-5
Hamel et al. Structural basis for the preferential association of autologous immunoglobulin subunits: role of the J region of the light chain
CA2180957A1 (fr) Clonage et production par recombinaison d'un ou plusieurs recepteurs du facteur liberateur de la corticotrophine
Lebovitz et al. The Amino Acid Sequence of the Fc Fragment of Rabbit Immunoglobulin G: I. THE ISOLATION AND AMINO ACID COMPOSITION OF TRYPTIC PEPTIDES